Table 5.
Stratification analysis of the prognostic value of SIRI on OS in digestive system carcinomas
| Subgroup | Number of studies | Pooled HR (95% CI) | Heterogeneity | Meta-regression (p value) |
tau2 | |
|---|---|---|---|---|---|---|
| I2 (%) | p value | |||||
| Country | 0.020 | |||||
| China | 21 | 1.71 (1.56–1.87) | 6.8 | 0.370 | 0.0033 | |
| Britain | 2 | 2.48 (1.80–3.40) | 0.0 | 0.476 | < 0.0001 | |
| Turkey | 1 | 2.86 (2.66–3.08) | - | - | < 0.0001 | |
| North America | 1 | 3.95 (2.47–6.31) | - | - | < 0.0001 | |
| Portugal | 1 | 2.75 (1.73–4.38) | - | - | < 0.0001 | |
| Sample number | 0.001 | |||||
| ≥ 220 | 13 | 1.61 (1.45–1.79) | 18.0 | 0.262 | 0.0085 | |
| < 220 | 13 | 2.72 (2.55–2.90) | 38.4 | 0.077 | 0.0210 | |
| Dividing line for SIRI | < 0.001 | |||||
| ≤ 1.2 | 14 | 1.58 (1.43–1.76) | 0.0 | 0.578 | < 0.0001 | |
| > 1.2 | 12 | 2.75 (2.58–2.93) | 22.0 | 0.227 | 0.0090 | |
| Treatment | < 0.001 | |||||
| With surgery | 15 | 1.60 (1.44–1.77) | 0.0 | 0.479 | < 0.0001 | |
| No surgery | 11 | 2.75 (2.57–2.93) | 29.0 | 0.169 | 0.0122 | |
| Cancer type | < 0.001 | |||||
| Esophageal cancer | 5 | 1.40 (1.20–1.64) | 0.0 | 0.536 | < 0.0001 | |
| Gastric cancer | 4 | 1.70 (1.40–2.06) | 0.0 | 0.481 | < 0.0001 | |
| Gallbladder cancer | 1 | 1.75 (1.03–2.99) | - | - | < 0.0001 | |
| Colorectal carcinoma | 1 | 2.39 (1.15–4.98) | - | - | < 0.0001 | |
| Pancreatic cancer | 10 | 2.75 (2.58–2.94) | 37.4 | 0.109 | 0.0170 | |
| Hepatocellular carcinoma | 3 | 2.06 (1.57–2.71) | 0.0 | 0.779 | < 0.0001 | |
| Cholangiocarcinoma | 1 | 1.89 (1.09–3.28) | - | - | < 0.0001 | |
| Gastroesophageal junction adenocarcinoma | 1 | 1.55 (1.10–2.18) | - | - | < 0.0001 | |
OS, overall survival; SIRI, systemic inflammation response index